INCYIncyte Corp.
INCY
Incyte Corp.5,594
Mkt Cap
$17.97BVolume
1.49M52W High
$112.2952W Low
$53.56PE Ratio
14.10INCY Fundamentals
Price
$90.30Prev Close
$92.26Open
$92.2850D MA
$99.07Beta
0.58Avg. Volume
1.96MEPS (Annual)
$6.41P/B
3.47Rev/Employee
$1.81M$16,297.46
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3...
Business Wire·1d ago
Incyte Corporation $INCY Shares Purchased by SG Americas Securities LLC
SG Americas Securities LLC raised its holdings in Incyte Corporation (NASDAQ:INCY - Free Report) by 627.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 186,790 shares of the biopharmaceutical company's stock after buying an additional 16...
MarketBeat·1d ago
Fairvoy Private Wealth LLC Acquires 24,865 Shares of Incyte Corporation $INCY
Fairvoy Private Wealth LLC lifted its holdings in shares of Incyte Corporation (NASDAQ:INCY - Free Report) by 468.8% during the 4th quarter, according to its most recent Form 13F filing with the...
MarketBeat·1d ago
Wealth Enhancement Advisory Services LLC Buys 20,988 Shares of Incyte Corporation $INCY
Wealth Enhancement Advisory Services LLC raised its stake in Incyte Corporation (NASDAQ:INCY - Free Report) by 19.7% during the fourth quarter, according to its most recent filing with the Securities...
MarketBeat·2d ago
UBS Group Lowers Incyte (NASDAQ:INCY) Price Target to $94.00
UBS Group reduced their price target on Incyte from $104.00 to $94.00 and set a "neutral" rating for the company in a report on Wednesday...
MarketBeat·4d ago
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data
Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis, raising questions on efficacy.
Zacks·4d ago
Incyte Announces Executive Leadership Appointments
Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Companys strategic focus and long-term growth plans. Pablo J. Cagnoni, M.D., has been appointed President, Incyte and Global Head of Research and Development. In this role, Dr. Cagnoni will retain...
Business Wire·4d ago
Incyte (NASDAQ:INCY) Earns Buy Rating from HC Wainwright
HC Wainwright reissued a "buy" rating and set a $135.00 target price on shares of Incyte in a research report on Wednesday...
MarketBeat·4d ago
Nordea Investment Management AB Acquires 291,293 Shares of Incyte Corporation $INCY
Nordea Investment Management AB increased its holdings in Incyte Corporation (NASDAQ:INCY - Free Report) by 941.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 322,223 shares of the biopharmaceutical com...
MarketBeat·5d ago
Swiss Life Asset Management Ltd Increases Stake in Incyte Corporation $INCY
Swiss Life Asset Management Ltd increased its stake in Incyte Corporation (NASDAQ:INCY - Free Report) by 180.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 85,480 shares of the...
MarketBeat·7d ago
<
1
2
...
>